Nimotop (Nimodipine)

Nimotop (nimodipine) is used in the cerebrovascular domain to reduce the risk of arterial narrowing after bleeding in the brain.

• Subarachnoid hemorrhage (SAH): prevents cerebral vasospasm and reduces the risk of delayed ischemic neurological deficits.
• Cerebrovascular disorders: enhances cerebral blood flow in patients with compromised cerebral circulation.
• Neurosurgical patients at risk of vasospasm: supports vascular stability during postoperative recovery.

• Nimodipine acts as a selective antagonist of L-type calcium channels located on vascular smooth muscle, especially in cerebral arteries. By inhibiting calcium influx, it causes preferential dilation of cerebral vessels, improving blood flow and lowering the likelihood of vasospasm after subarachnoid hemorrhage.

Nimotop may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness.
• Flushing or warmth sensation.
• Nausea or gastrointestinal discomfort.
• Low blood pressure (hypotension).
• Peripheral edema.

Serious or Rare Side Effects

• Severe hypotension or syncope.
• Bradycardia or cardiac arrhythmias.
• Hepatic dysfunction or elevated liver enzymes.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hemorrhagic complications in susceptible patients.

Before initiating therapy, consider the following safety measures.

• Pregnancy: safety not established; avoid unless benefit outweighs potential risk.
• Breastfeeding: unknown excretion; caution advised.
• Hepatic impairment: use with caution; monitor liver function.
• Concomitant antihypertensives: may potentiate blood‑pressure lowering effects; monitor closely.
• Blood pressure monitoring: check regularly, especially after dose adjustments.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Nimotop can interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels.
• Other calcium‑channel blockers: additive hypotensive effect.
• Potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Diuretics: can enhance hypotensive response.
• Antihypertensive agents: dose adjustments may be needed.
• NSAIDs: may affect renal function when combined with hypotension.
• Alcohol: can increase dizziness and hypotension.